Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: To report a rare case of immune checkpoint inhibitor (ICI)- associated bilateral choroidal neovascularization (CNV) and sunset glow fundus appearance in a pediatric patient receiving long-term nivolumab therapy.
Method: Observational case report.
Case Report: A 15-year-old male with metastatic myoepithelial carcinoma, on nivolumab for 2.5 years, presented with bilateral blurred vision. Fundus examination revealed a sunset glow fundus, punched-out lesions, and CNV in both eyes. Optical coherence tomography (OCT) confirmed inflammatory CNV with choroidal thickening. Nivolumab was discontinued, and the patient received systemic corticosteroids and intravitreal ranibizumab. Despite initial improvement, CNV recurred upon steroid tapering, requiring additional anti-VEGF injections. At four months, vision stabilized with no CNV reactivation.
Conclusion: This case represents the first pediatric report of ICI- associated bilateral CNV and sunset glow fundus appearance. It underscores the importance of monitoring for late-onset immune-related ocular complications in patients on long-term nivolumab therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/09273948.2025.2524584 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ultrawidefield Optical Coherence Tomography Angiography in the Mid-Periphery and Macula of Vogt-Koyanagi-Harada Disease.
Ocul Immunol Inflamm
August 2025
Ophthalmologic Center of the Second Hospital, Jilin University, Changchun, P.R. China.
Purpose: To investigate ultrawidefield optical coherence tomography angiography (UWF-OCTA) changes in the mid-periphery of new-onset active Vogt-Koyanagi-Harada (VKH) patients.
Methods: New-onset and untreated active VKH patients were continuously observed using UWF-OCTA at 2 weeks, 1, and 3 months after treatment.
Results: Twenty-four new-onset and untreated active VKH patients were included.
Clinical characteristics and visual outcome of Vogt Koyanagi Harada disease patients in a specialized eye hospital in Nepal.
J Nepal Health Res Counc
June 2025
Department of Uveitis, Tilganga Institute of Ophthalmology, Gaushala, Kathmandu, Nepal.
Background: To evaluate clinical characteristics and visual outcome of Vogt-Koyanagi-Harada disease patients in Nepal.
Methods: Retrospective series of all the cases of VKH treated at Tilganga Institute of Ophthalmology from 1st July 2017 to 31st June 2022.
Results: Fifty-four cases were included, 18(33.
Predictive factors at initial visit for sunset glow fundus in Vogt-Koyanagi-Harada disease.
Sci Rep
July 2025
Department of Ophthalmology, Fukushima Medical University, Fukushima, 960-1295, Japan.
This study aimed to identify factors present at the initial visit for the development of sunset glow fundus (SGF) in Vogt-Koyanagi-Harada (VKH) disease. A total of 139 eyes from 70 naïve patients with acute VKH disease who underwent pulse steroid therapy were categorized into "SGF" and "non-SGF" groups based on fundus appearance at 12 months post-therapy. Multivariable analysis revealed that patients with meningismus (p = 0.
View Article and Find Full Text PDFSunset Glow Fundus and Bilateral Choroidal Neovascularization in a Pediatric Patient Receiving Nivolumab: A Rare Pediatric Immune-Related Ocular Complication.
Ocul Immunol Inflamm
July 2025
Department of Pediatric Oncology, Medicana Zincirlikuyu Hospital, Istanbul, Turkey.
Purpose: To report a rare case of immune checkpoint inhibitor (ICI)- associated bilateral choroidal neovascularization (CNV) and sunset glow fundus appearance in a pediatric patient receiving long-term nivolumab therapy.
Method: Observational case report.
Case Report: A 15-year-old male with metastatic myoepithelial carcinoma, on nivolumab for 2.
Comparative study of efficacy and safety of pulse versus half-pulse steroid therapy for Vogt-Koyanagi-Harada Disease.
Jpn J Ophthalmol
September 2025
Department of Ophthalmology, Tokyo Medical University Hospital, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
Purpose: High-dose steroid therapy is commonly used for Vogt-Koyanagi-Harada (VKH) disease in Japan, but the optimal initial dose remains uncertain. This study investigated the efficacy and safety of conventional steroid pulse therapy (pulse group) and half-dose steroid pulse therapy (half-pulse group) for the initial treatment of VKH disease.
Study Design: This was a single-center, retrospective observational study based on a review of medical records.